Dec 6, 2025 8:30:00 PM
Streamlined sample preparation of DoA panel in human nails using ISOLUTE® SLE+
By Biotage
Figure 1. Example structures by class.
Introduction
The testing of alternative matrices in forensic and/or clinical toxicology is gaining popularity, partly due to less invasive means of collection. Matrices such as hair or nail can provide a more rounded picture of abstinence or abuse and associated timeframes. This application note describes the sample pre-treatment and subsequent extraction of 49 drugs of abuse from human nails, prior to LC/MS analysis.
The method utalizes Biotage® Lysera for matrix micropulverization, prior to direct transfer to clean up using ISOLUTE® SLE+ supported liquid extraction products. Elimination of an evapo- ration step between the micropulverization and supported liquid extraction clean up stages provides a streamlined procedure for nail extraction.
Manual processing protocols were developed using the Biotage® PRESSURE+ 96 (plate format) or 48 (column format) Positive Pressure Manifolds. For automated processing, protocols were developed using Biotage® ExtraheraTM.
This application note contains procedures optimized for both individual column format and 96-well plate format for higher throughput applications. The methodology delivers clean extracts and analyte recoveries mostly greater than 80% with RSDs lower than 10% for all analytes and LLOQ from 1 pg/mg.
Both manual and automated procedures gave comparable results.
ISOLUTE® SLE+ Supported Liquid Extraction plates and cartridges offer an efficient alternative to traditional liquid- liquid extraction (LLE) for bioanalytical sample preparation, providing high analyte recoveries, no emulsion formation and significantly reduced preparation time.
Analytes
Amphetamine, Methamphetamine, 3,4-Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 3,4-Methylenedioxy-N-ethylamphetamine (MDEA), Hydromorphone, Morphine, Benzoylecgonine (BZE), Oxymorphone, Dihydrocodeine, Oxycodone, Mephedrone, Norfentanyl, 7-amino-flunitrazepam, 7-amino-clonazepam, Hydrocodone, Codeine, 6-Monoacetylmorphine (6-MAM), Cocaine, Norketamine, 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), Zaleplon, Zopiclone, Norbuprenorphine, Ketamine, Nitrazepam, Flunitrazepam, Clonazepam, α-OH-triazolam, Oxazepam, Estazolam, Temazepam, Zolpidem, Alprazolam, Methadone, Lorazepam, Bromazepam, α-OH-alprazolam, 2-OH-ethyl-flurazepam, Triazolam, Nordiazepam, Diazepam, Midazolam, Fentanyl, Flurazepam, Buprenorphine, Phencyclidine (PCP), Lysergic acid diethylamide (LSD)
Internal standards
Amphetamine-D5, Morphine-D3, Benzoylecgonine-D3 (BZE-D3), 6-Monoacetylmorphine-D3 (6-MAM-D3), Diazepam-D5
Sample preparation procedure
Format
ISOLUTE® SLE+ 400 µL capacity cartridges. (p/n 820-0055-B) or ISOLUTE® SLE+ 400 µL capacity plates (p/n 820-0400-P01)
Matrix preparation
Weigh 10 mg of freshly clipped nails into 2 mL Biotage® Lysera tubes (p/n 19-620) containing 5 x 2.4 mm stainless steel beads (p/n 19-640).
Micropulverization procedure
Grind to a fine powder using Biotage® Lysera: 8 x 6.95 m/sec for 45 seconds with a 45s dwell.
Add 1 mL methanolic 0.1% (v/v) NH4OH to each nail sample after micropulverization. Also add 10 µL of a 100 pg/mL ISTD solution giving a 100 pg/mg spike.Mix.
Centrifuge tubes for 10 minutes at 13,300 rpm (Heraeus Pico 17 Microcentrifuge (Thermo Scientific) with 24 position, 2 mL rotor).
Post micropulverisation
Transfer an aliquot of supernatant directly to the appropriate ISOLUTE SLE+ product for clean up as described below.
Supported liquid extraction conditions
|
|
ISOLUTE® SLE+ 400 µL Cartridges |
ISOLUTE® SLE+ 400 µL Plate |
|
Sample loading |
Load up to 400 µL of supernatant directly to ISOLUTE® SLE+ sorbent. Note: A pulse of pressure is not needed to initiate flow with methanolic loads. Allow the sample to absorb for 5 minutes. |
Load up to 400 µL of supernatant directly to ISOLUTE® SLE+ sorbent. Note: A pulse of pressure is not required to initiate flow with methanolic loads. Allow the sample to absorb for 5 minutes. |
|
Analyte Extraction |
Apply DCM/IPA (95/5, v/v, 600 µL) and allow to flow under gravity for 5 minutes. Apply a further aliquot of MTBE (600 µL) and allow to flow under gravity for 5 minutes. To complete solvent removal apply a pulse of positive pressure at 10 psi (10–20 seconds). |
Apply DCM/IPA (95/5, v/v, 600 µL) allow to flow under gravity for 5 minutes. Apply a further aliquot of MTBE (600 µL) and allow to flow under gravity for 5 minutes. To complete solvent removal apply a pulse of positive pressure at 10 psi (10-20 seconds). |
|
Collection vessels |
Collect extract in 12x75 mm glass tubes |
Collect extract in 96-well collection plates. |
|
Post elution |
Evaporate extracts at 40 °C, in the presence of 100 µL of 50 mM HCl in MeOH per tube in order to avoid evaporative losses of amphetamines, for 30 mins at a flow rate of 1.5 L/min using a TurboVap® LV. |
Evaporate extracts at 40 °C, in the presence of 100 µL of 50 mM HCl in MeOH per well in order to avoid evaporative losses of amphetamines, for 30 mins at a flow rate of 20-40 L/min using the Biotage® SPE Dry-96. |
|
Reconstitute |
Reconstitute extracts in a mix of mobile phase A/mobile phase B (80:20, v/v, 200 µL). Vortex mix, transfer into a 96-well format plate and cover with a sealing mat prior to injection. |
Reconstitute extracts in a mix of mobile phase A/ mobile phase B (80:20, v/v, 200 µL). Vortex mix. Cover plate with a sealing mat prior to injection. |
UHPLC conditions
Instrument
Shimadzu Nexera X2 UHPLC
Column
Restek Raptor™ Biphenyl 2.7 µm (100 x 2.1 mm) with a Restek EXP holder and Biphenyl guard column
Mobile phase
A: 2 mM Ammonium formate (aq) with 0.1% formic acid
B: 2 mM Ammonium formate in methanol with 0.1% formic acid
Flow rate
0.4 mL/min
Injection volume
5 µL
Column temperature
30 °C
Table 1. UHPLC gradient.
|
Time (min) |
%A |
%B |
|
0 |
80 |
20 |
|
2.00 |
80 |
20 |
|
7.50 |
40 |
60 |
|
11.25 |
40 |
60 |
|
12.75 |
0 |
100 |
|
13.50 |
0 |
100 |
|
13.51 |
80 |
20 |
|
15.00 |
80 |
20 |
Mass spectrometry conditions
Instrument
Shimadzu 8060 Triple Quadrupole MS using ES interface
Nebulizing gas flow
3 L/min
Drying gas flow
3 L/min
Heating gas flow
17 L/min
Interface temperature
400 oC
DL temperature
250 oC
Heat block temperature
300 oC
CID gas flow
270 kPa
Table 2. MS conditions for target analytes in positive mode.

Results
This simple sample preparation method delivers clean extracts and analyte recoveries mostly greater than 80% with RSDs lower than 10% for all analytes (see fig 2), and LLOQs from 1pg/mL (see table 3) for all ISOLUTE® SLE+ formats used.
Figure 2. Representative analyte recoveries using the optimized ISOLUTE® SLE+ protocol for the 400 µL capacity cartridge format (p/n 820-0055-B) with manual or automated processing. Similar results were achieved using the 400 µL capacity plate formats.
Figure 3. Representative chromatography for application analytes spiked at 1 ng/mL.
Linearity was investigated for human nails spiked between 1–1000 pg/mg. Good linearity was observed for all analytes delivering r2 values greater than 0.99. Table 3. details linearity performance and associated LOQ for each analyte, using the 400 µL capacity column format, p/n 820-0055-B. Similar results were obtained from both columns and plate formats, with either manual or automated processing.
Table 3. Analyte calibration curve r2 and LOQ performance.
|
Analytes |
400 µL Load r2 |
400 µL Load LLOQ (pg/mL) |
Analytes |
400 µL Load r2 |
400 µL Load LLOQ (pg/mL) |
|
Morphine |
0.999 |
1 |
Zolpidem |
0.999 |
< 1 |
|
Oxymorphone |
0.999 |
<1 |
Buprenorphine |
0.999 |
< 1 |
|
Hydromorphone |
0.999 |
< 1 |
Fentanyl |
0.997 |
< 1 |
|
Amphetamine |
0.994 |
1 |
Flurazepam |
0.999 |
< 1 |
|
Methamphetamine |
0.999 |
< 1 |
PCP |
0.999 |
< 5 |
|
MDA |
0.997 |
5 |
Midazolam |
0.998 |
< 1 |
|
Dihydrocodeine |
0.999 |
< 1 |
Bromazepam |
0.999 |
< 5 |
|
Codeine |
0.999 |
< 1 |
EDDP |
0.998 |
< 1 |
|
6-MAM |
0.999 |
< 1 |
Lorazepam |
0.997 |
10 |
|
MDMA |
0.999 |
< 1 |
Oxazepam |
0.997 |
5 |
|
Oxycodone |
0.997 |
< 1 |
Nitrazepam |
0.998 |
1 |
|
Mephedrone |
0.999 |
< 1 |
Clonazepam |
0.998 |
1 |
|
Hydrocodone |
0.999 |
< 1 |
a-OH-Triazolam |
0.999 |
< 5 |
|
MDEA |
0.999 |
< 1 |
2-OH-et-flurazepam |
0.999 |
1 |
|
Nor-Ketamine |
0.998 |
< 1 |
Methadrone |
0.997 |
5 |
|
Nor-Fentanyl |
0.999 |
< 1 |
a-OH-Alprazolam |
0.999 |
5 |
|
BZE |
0.993 |
< 1 |
Nordiazepam |
0.999 |
1 |
|
Ketamine |
0.999 |
< 1 |
Zaleplon |
0.999 |
< 1 |
|
7-Aminoclonazepam |
0.996 |
< 1 |
Flunitrazepam |
0.999 |
1 |
|
Cocaine |
0.995 |
< 1 |
Estazolam |
0.999 |
1 |
|
Zopiclone |
0.999 |
1 |
Temazepam |
0.998 |
1 |
|
Norbuprenorphine |
0.999 |
5 |
Triazolam |
0.999 |
< 1 |
|
LSD |
0.996 |
5 |
Alprazolam |
0.999 |
5 |
|
7-Aminoflunitrazepam |
0.997 |
1 |
Diazepam |
0.998 |
1 |
Figure 4. Calibration curves for Buprenorphine (a), 6-MAM (b), BZE (c) and Methamphetamine (d) extracted from human nails using the 400 µL capacity column format loading 400 µL of extract (manual processing). Similar results were achieved for the 400 µL capacity plate formats, and for automated processing procedures.
Chemicals and reagents
- Methanol (LC-MS grade), Ultra-Pure Methanol (Gradient MS), dichloromethane (99.8%), isopropanol (99.9%), MTBE (99%) and formic acid (98%) were purchased from Honeywell Research Chemicals (Bucharest, Romania).
- All analyte standards and deuterated internal standards, hydrochloric acid (37%) and ammonium formate (LC-MS grade) were purchased from Sigma- Aldrich Company Ltd. (Gillingham, UK).
- Ammonium hydroxide (28–30%) was purchased from Merck.
- Water used was 18.2 MOhm-cm, drawn daily from a Direct-Q5 water purifier.
- 0.1% NH4OH was prepared by adding 100 µL of ammonium hydroxide to 99.9 mL of methanol
- 50mM HCl in MeOH was prepared by adding 50 µL of hydrochloric acid to l to 12 mL of methanol.
- DCM: IPA (95:5, v/v) was prepared by adding 5 mL of isopropanol to 95 mL of DCM and mixing.
- Mobile phase A (2 mM ammonium formate (aq), 0.1 % formic acid) was prepared by adding 126 mg of ammonium formate to 500 mL of purified water, adding 1 mL of concentrated formic acid and making up to 1 L with purified water.
- Mobile phase B (2 mM ammonium formate (methanol), 0.1 % formic acid) was prepared by adding 126 mg of ammonium formate to 500 mL of HPLC grade methanol, adding 1 mL of concentrated formic acid and making up to 1 L with HPLC grade methanol.
- Internal standards( 100 pg/µL) were prepared from a 10 ng/µL stock solution by adding 10 µL of each of to 950 µL of MeOH. 10 µL of this solution was then added to each calibration.
Additional information
- All data shown in this application note was generated using freshly clipped nails provided by healthy human volunteers.
- Biotage®Lysera hints and tips.
- A minimum of four tubes must be loaded in the tube carriage to ensure balance during processing.
- Ensure vial caps are firmly tightened and Lysera locking mechanism is fully engaged.
- To minimize sample transfer and manipulation steps, 2 mL Lysera tubes were placed directly into the centrifuge (Heraeus Pico 17 Microcentrifuge (Thermo Scientific) with 24 position, 2 mL rotor).
Ordering information
|
Part Number |
Description |
Quantity |
|
19-060 |
Biotage® Lysera |
1 |
|
19-649 |
2 mL Reinforced Tubes with screw caps (Bulk pack) |
1000 |
|
19-640 |
2.4 mm Metal Beads - 500 grams |
1 |
|
820-0055-B |
ISOLUTE® SLE+ 400 µL sample volume cartridges |
50 |
|
820-0400-P01 |
ISOLUTE® SLE+ 400 µL Capacity Plate |
1 |
|
PPM-96 |
Biotage® PRESSURE+ 96 Positive Pressure Manifold |
1 |
|
PPM-48 |
Biotage® PRESSURE+ 48 Positive Pressure Manifold |
1 |
|
415000 |
TurboVap® LV |
1 |
|
SD-9600-DHS-EU |
Biotage® SPE Dry 96 Sample Evaporator 220/240 V |
1 |
|
SD-9600-DHS-NA |
Biotage® SPE Dry 96 Sample Evaporator 100/120 V |
1 |
|
121-5203 |
Collection Plate, 2 mL Square |
50 |
|
121-5204 |
Piercable Sealing Mat |
50 |
|
C44651 |
Test Tubes (12 x 75 mm, Uncapped) |
1000 |
|
414001 |
Biotage® Extrahera™ |
1 |
Appendix: Biotage® Extrahera™ settings
The method described in this application note was automated on the Biotage® Extrahera™ using ISOLUTE® SLE+ 400 µL capacity cartridges and 96-well plates. This appendix contains the software settings required to configure Extrahera to run the column format method. As described in the main body of the application note, analyte recoveries, %RSDs, linearities and LOQs were comparable for both manually processed and automated methods, for both extraction formats.



Solvent Properties
|
|
Solvent Description |
|
1 |
DCM:IPA (95:5) |
|
2 |
MTBE |
|
3 |
|
|
4 |
|
|
5 |
|
|
6 |
|
|
7 |
|
|
8 |
|
|
9 |
|
|
10 |
|
|
Solvent |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
|
Reservoir Type |
Refillable |
Non Refillable |
||||||||
|
Capacity |
||||||||||
|
Aspiration flow rate (mL/min) |
10 |
10 |
||||||||
|
Dispense flow rate (mL/min) |
10 |
10 |
||||||||
|
Lower air gap flow rate (mL/min) |
10 |
10 |
||||||||
|
Lower air gap volume (µL) |
5 |
5 |
||||||||
|
Upper air gap flow rate (mL/min) |
120 |
120 |
||||||||
|
Upper air gap volume (µL) |
100 |
100 |
||||||||
|
Upper air gap dispense pause |
300 |
300 |
||||||||
|
Conditioning? |
Yes |
Yes |
||||||||
|
Conditioning number of times |
2 |
2 |
||||||||
|
Conditioning flow rate (mL/min) |
10 |
10 |
||||||||
|
Chlorinated |
Yes |
No |
||||||||
|
Serial dispense |
No |
No |
||||||||




Literature Number: AN916
Published: Dec 6, 2025 8:30:00 PM